ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Kura Oncology (KURA)
Kura Oncology stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$9.90▲ +2.91%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
48%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Kura Oncology in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Kura Oncology
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Kura Oncology a 48% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $9.03 and $10.75; in 9 out of 10, between $7.74 and $12.55. Estimated annual volatility is 49%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $947M
- 52-week high
- $13.90
- 52-week low
- $7.36
- Revenue (12 months)
- $77.2M
- Revenue growth (YoY)
- +25.2%
- Gross margin
- 99.9%
- Operating margin
- -449.9%
- Net margin
- -412.9%
- Return on equity
- -167.7%
- Free cash flow (12 months)
- $-166M
- Beta
- 0.43
What this means
ATLAS does not publish a fair value for KURA right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks KURA has traded between $7.36 and $13.90. Today it is 28.8% below that high and 35% above its low.
On the business: revenue grew 25.2% year over year; net margin is 412.9%.
Its beta is 0.43: it tends to move less than the market.
About the company
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer.
Want to see everything about Kura Oncology?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Kura Oncology do?
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer.
What is the chance KURA goes up next month?
48%: close to a coin flip. In half of the simulated outcomes, KURA ends the month between $9.03 and $10.75.
How big is Kura Oncology and what is its P/E ratio?
Kura Oncology's market capitalization is $947M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is KURA?
ATLAS estimates annual volatility at 49%. In a typical month, half of the outcomes end between $9.03 and $10.75.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer